{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:24:01Z","timestamp":1789097041524,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR22\/00041"],"award-info":[{"award-number":["JR22\/00041"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1053\/j.seminhematol.2024.01.004","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T04:47:18Z","timestamp":1705812438000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A tower of babel of acronyms? The shadowlands of MGUS\/MBL\/CHIP\/TCUS"],"prefix":"10.1053","volume":"61","author":[{"given":"Carlos","family":"Bravo-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0001","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/hematology.2021000276","article-title":"Have we reached a molecular era in myelodysplastic syndromes?","volume":"2021","author":"Voso","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.004_bib0002","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1056\/NEJMra1312543","article-title":"Diagnostic clinical genome and exome sequencing","volume":"370","author":"Biesecker","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.004_bib0003","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.004_bib0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.004_bib0005","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.004_bib0006","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.004_bib0007","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.004_bib0008","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S2352-3026(23)00086-8","article-title":"Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?","volume":"10","author":"Semenzato","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.01.004_bib0009","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.004_bib0011","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.004_bib0012","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.004_bib0013","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.004_bib0014","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/hematology.2020000122","article-title":"Monoclonal gammopathies of clinical significance","volume":"2020","author":"Dispenzieri","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.01.004_bib0016","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.004_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.004_bib0018","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.004_bib0019","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0021","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.004_bib0022","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.004_bib0023","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.004_bib0024","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/bloodadvances.2021005354","article-title":"Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies","volume":"6","author":"Bagratuni","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.004_bib0026","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.004_bib0027","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1309\/6U88-357U-UKJ5-YPT3","article-title":"Cytogenetic findings in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course","volume":"116","author":"Mansoor","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.004_bib0028","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","article-title":"The cellular origin and malignant transformation of Waldenstr\u00f6m macroglobulinemia","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.004_bib0029","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.004_bib0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\u00f6m Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.004_bib0031","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.004_bib0032","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.004_bib0033","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"Suppl_1","key":"10.1053\/j.seminhematol.2024.01.004_bib0034","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2019-129103","article-title":"A phase II study of daratumumab in patients with high-risk mgus and low-risk smoldering multiple myeloma: first report of efficacy and safety","volume":"134","author":"Nadeem","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.004_bib0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.004_bib0036","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.004_bib0037","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1056\/NEJMoa075290","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"359","author":"Rawstron","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0038","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2009-01-197368","article-title":"Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach","volume":"114","author":"Nieto","year":"2009","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2024.01.004_bib0039","first-page":"S4","article-title":"Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection","volume":"78","author":"Nieto","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.004_bib0040","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood-2013-08-523704","article-title":"Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding","volume":"123","author":"Shim","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.004_bib0041","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1182\/blood-2011-05-357251","article-title":"General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL","volume":"118","author":"Fazi","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.004_bib0042","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/leu.2011.117","article-title":"Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL","volume":"25","author":"Lanasa","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0043","first-page":"S42","article-title":"Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing","volume":"78","author":"Rawstron","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.004_bib0044","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1158\/1078-0432.CCR-13-0622","article-title":"Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features","volume":"19","author":"Morabito","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.01.004_bib0045","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2022.04.010","article-title":"Monoclonal B-cell lymphocytosis in the bone marrow: revisiting the criteria for chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"125","author":"Ryder","year":"2022","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.004_bib0046","doi-asserted-by":"crossref","first-page":"e67751","DOI":"10.1371\/journal.pone.0067751","article-title":"Combined patterns of IGHV repertoire and cytogenetic\/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia","volume":"8","author":"Henriques","year":"2013","journal-title":"PloS one"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.004_bib0047","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-12-471698","article-title":"Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL","volume":"121","author":"Vardi","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.004_bib0048","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2017.177212","article-title":"Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations","volume":"103","author":"Agathangelidis","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0049","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07711.x","article-title":"The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors","volume":"146","author":"Rossi","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0050","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2016.172","article-title":"Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome","volume":"31","author":"Barrio","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.004_bib0051","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bjh.12800","article-title":"High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications","volume":"165","author":"Lionetti","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.004_bib0052","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.004_bib0053","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/leu.2017.246","article-title":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group","volume":"31","author":"Hoechstetter","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.004_bib0054","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.004_bib0055","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.004_bib0056","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.004_bib0057","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.004_bib0058","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2017.181","article-title":"CHIP, ICUS, CCUS and other four-letter words","volume":"31","author":"Bejar","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.004_bib0059","first-page":"128","article-title":"From clonal hematopoiesis to therapy-related myeloid neoplasms: the silent way of cancer progression","volume":"10","author":"Gurnari","year":"2021","journal-title":"Biology (Basel)"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.01.004_bib0060","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.01.004_bib0061","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"6465","key":"10.1053\/j.seminhematol.2024.01.004_bib0062","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.01.004_bib0063","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.01.004_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107038","article-title":"From bone marrow failure syndromes to VEXAS: disentangling clonal hematopoiesis, immune system, and molecular drivers","volume":"127","author":"Gurnari","year":"2023","journal-title":"Leuk Res"},{"issue":"7784","key":"10.1053\/j.seminhematol.2024.01.004_bib0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-019-1765-3","article-title":"Genetic predisposition to mosaic Y chromosome loss in blood","volume":"575","author":"Thompson","year":"2019","journal-title":"Nature"},{"issue":"7463","key":"10.1053\/j.seminhematol.2024.01.004_bib0066","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"7714","key":"10.1053\/j.seminhematol.2024.01.004_bib0067","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.004_bib0068","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/ng.2271","article-title":"Detectable clonal mosaicism from birth to old age and its relationship to cancer","volume":"44","author":"Laurie","year":"2012","journal-title":"Nat Genet"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.004_bib0069","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3324\/haematol.2013.085548","article-title":"Nature and importance of follicular lymphoma precursors","volume":"99","author":"Mamessier","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.01.004_bib0070","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.004_bib0071","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.004_bib0072","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.004_bib0073","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.004_bib0074","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.004_bib0075","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0076","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s42003-020-01220-9","article-title":"Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia","volume":"3","author":"Guan","year":"2020","journal-title":"Commun Biol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.004_bib0077","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215236","article-title":"LGL clonal expansion and unexplained cytopenia: two clues don't make an evidence","volume":"14","author":"Calabretto","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.004_bib0078","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/s41375-022-01695-x","article-title":"All that glitters is not LGL Leukemia","volume":"36","author":"Semenzato","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.01.004_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101058","article-title":"Not all LGL leukemias are created equal","volume":"60","author":"Semenzato","year":"2023","journal-title":"Blood Rev"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.004_bib0080","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/s41375-020-01114-z","article-title":"Novel invariant features of Good syndrome","volume":"35","author":"Gurnari","year":"2021","journal-title":"Leukemia"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.004_bib0081","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.004_bib0082","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-019-0601-y","article-title":"Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome","volume":"34","author":"Durrani","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0083","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40164-023-00403-4","article-title":"New approaches to idiopathic neutropenia in the era of clonal hematopoiesis","volume":"12","author":"Ogbue","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.01.004_bib0084","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174418","article-title":"Large granular lymphocytic leukemia: from immunopathogenesis to treatment of refractory disease","volume":"13","author":"Zawit","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.004_bib0085","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.3390\/cells10102800","article-title":"Neutropenia and large granular lymphocyte leukemia: from pathogenesis to therapeutic options","volume":"10","author":"Calabretto","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.004_bib0086","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1038\/s41467-022-31015-x","article-title":"Defining TCR\u03b3\u03b4 lymphoproliferative disorders by combined immunophenotypic and molecular evaluation","volume":"13","author":"Teramo","year":"2022","journal-title":"Nat Commun"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.01.004_bib0087","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.004_bib0088","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","article-title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia","volume":"121","author":"Rajala","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.01.004_bib0089","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2016-06-724856","article-title":"High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia","volume":"128","author":"Andersson","year":"2016","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T20:27:43Z","timestamp":1729110463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0037196324000027"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tower of babel of acronyms? The shadowlands of MGUS\/MBL\/CHIP\/TCUS","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}